Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Financing › Details

Swixx Biopharma–SEVERAL: investment, 202105– capital increase €45m with €40m from new investor MxEP + €5m from existing investor HBM

 

Period Period 2021-05-20
Region Region East Europe
Organisations Money taker Swixx Biopharma AG
  Today Swixx Biopharma (Group)
  Group Swixx Biopharma (Group)
  Money source SEVERAL
Products Product pharmaceutical
  Product 2 private equity
     

Swixx Biopharma AG. (5/20/21). "Press Release: Swixx Welcomes Mérieux Equity Partners as Minority Shareholder and Announces €45 Million Capital Increase". Baar.

Swixx Biopharma AG of Baar, Switzerland announced today the signature of an investment agreement with Mérieux Equity Partners (MxEP) of Lyon, France, whereby MxEP will invest €40 million into Swixx, taking a minority position. In addition, HBM Healthcare Investments (HBM) of Zug, Switzerland, who had invested in Swixx in 2017, will co-invest alongside Mérieux, increasing HBM’s investment in Swixx by €5 million. HBM’s and MxEP’s investments should close during the next few months, depending upon completion of routine regulatory approvals. The new capital will be used to leverage the steady growth that Swixx has enjoyed over the past few years. MxEP has arrangements in place to increase its investment in Swixx up to €90 million, based upon the realisation of certain milestones. MxEP’s Managing Partner Benoît Chastaing will join Swixx’s Board.

“It is a great pleasure to welcome MérieuxEquity Partners,” commented Swixx co-founder Michael Seeley. “We are honoured that such a well-regarded healthcare fund as MxEP has seen fit to invest in Swixx. The Mérieux family’s long history of scientific innovation speaks for itself, and we feel privileged to be associated with such a partner. It’s my hope that Swixx, bolstered with this new infusion of €45 million cumulatively in growth capital, will be able to access even more new opportunities in acquisitions, licensing, and portfolio expansion. We look forward to work together with Benoît and his team.”

“We are delighted to partner with Swixx’s management team, founders and HBM,” said Benoît Chastaing, Managing Partner at MxEP. “We look forward to support the company in its next development phase. We have been impressed by how quickly Swixx has established itself as a reputable partner for biopharma clients based upon the highest standards of professionalism, knowledge and service. Mérieux aims to deploy its own expertise and industrial network to support Swixx’s future growth.”

Barclays Bank PLC, acting through its investment bank (Barclays) acted as financial advisor and Walder Wyss AG (Zurich) acted as legal advisor to Swixx. In turn, Rothschilds & Co acted as financial adviser and Baker McKenzie (Zurich) acted as legal advisor to MxEP.


About Swixx Biopharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, and Russia. With 600 employees and sales exceeding €260 million in 2021, Swixx has swiftly evolved into the largest and fastest-growing dedicated commercialization platform for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com


About MérieuxEquity Partners

Mérieux Equity Partners ("MxEP") is an AMF-accredited management company dedicated to equity investments in the health and nutrition sector. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. MxEP currently manages over €1 billion in assets and has just launched its fifth vehicle – dedicated to growth capital/LBO investments – with a target size of €500 million. For further information about MxEP, please visit: www.merieux-partners.com


About HBM Healthcare Investments

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN). For further information about HBM, please visit: www.hbmhealthcare.com/en/

Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.
Maja.Boskovic@swixxbiopharma.com
Tel: +381 11 4426 321

   
Record changed: 2021-05-28

Advertisement

Picture Excelya CRO Your Trial Across Europe 650x80px

More documents for Swixx Biopharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top